OS Therapies Inc. ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported full-year 2024 financial results ended ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback